Click here to close now.




















Welcome!

News Feed Item

University of Maryland School of Medicine Scientist is at Forefront of Developing Vaccine for Ebola Virus

Alan Schmaljohn, Ph.D. has studied Ebola virus for decades through U.S. Army Medical Research Institute for Infectious Disease

BALTIMORE, Aug. 12, 2014 /PRNewswire-USNewswire/ -- As the number of lives taken by the Ebola virus in West Africa has surpassed 1,000, and the U.S. prepares as rapidly as it can, it is clear that little is known in the medical community about the virus. In fact, some experts point out that the number of medical professionals who can properly diagnose and recommend the next steps for treatment is alarmingly small.

Some scientists, however, like Alan Schmaljohn, Ph.D., Professor of Microbiology and Immunology at the University of Maryland School of Medicine (UM SOM), have spent decades studying the Ebola virus and similar viruses identifying key characteristics that have aided in the development of vaccines, antivirals and treatment methods.                                                                                         

As a leader of research and Chief in the Viral pathogenesis and Immunology Branch with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Dr. Schmaljohn was able to help identify three of the key antibodies that are used currently in combination with each other to treat patients infected with Ebola.

Dr. Schmaljohn is now one of the scientific leaders in the UM SOM partnership with Department of Defense contract recipient Paragon Bioservices in the manufacture of an Ebola virus vaccine for initial safety testing in humans.

"Several vaccine candidates for Ebolavirus are proceeding through initial manufacture toward safety testing in human volunteers," Dr. Schmaljohn said.  "Different vaccine candidates are based upon different 'platforms' in which selected viral proteins may be made 'in the test tube' and purified for injection, or may be added genetically as passengers of a different variety of virus that is weakened. Only human trials will provide the final answers as to which vaccines are best on the basis of many criteria, foremost being safety and efficacy," he said.

Dr. Schmaljohn was originally one of the leaders in determining what kinds of immune responses are required for protection against viruses like Ebola and he was part of the team that first identified antibodies capable of protecting certain animals from Ebola virus.  "Subsequently," he said, "three of these antibodies have been developed as a candidate mixture for human therapy against Ebolavirus, which seems to be true with an American who was infected with Ebolavirus during the current outbreak."  However, he cautions that many scientific questions remain unanswered. 

E. Albert Reece, M.D., Ph.D., M.B.A., Vice President of Medical Affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the UM SOM, said, "We are grateful to have scientists at the UM SOM like Dr. Schmaljohn who have studied viruses like Ebola for decades.  We can now build on that knowledge and understanding to focus on bridging the science to the development of new vaccines.  The University of Maryland School of Medicine is well-positioned to play an integral role in addressing this serious public health issue."

The UM SOM has been an international leader in both vaccine development and study of infectious disease for many years with longstanding support from NIH and other federal agencies.

Scientists in the School's Department of Microbiology and Immunology, under the leadership of James B. Kaper, Ph.D, have opened new approaches to the basic and applied aspects of infectious diseases and host defenses.  They are applying these approaches to basic aspects of receptor signaling, regulation of gene expression in both prokaryotic and eukaryotic cells and interactions between these cells, genetic manipulation of cellular functions, microbial genomics and evolution, and development of new vaccination strategies. The techniques of functional genomics, gene delivery, stem cells and transgenic/gene disruption animal models are being developed to address specific questions.

The pioneering work of the UM SOM's Center for Vaccine Development, under Myron Levine, M.D., D.T.P.H., founded the discipline now known as "vaccinology," which incorporates measurement of the burden of a disease to direct vaccine research; construction of vaccine candidates; clinical trials to demonstrate the safety of a vaccine and its ability to stimulate immune responses and to protect against disease; and documentation of the public health impact that follows introduction of the vaccine into widespread use.  The earliest NIH-supported formal training programs in the field of vaccinology were established by Dr. Levine at the SOM.  It was, and still is, funded with a T32 Grant from the National Institutes of Health (NIH). Dr. Levine has also oriented the discipline at Maryland to address the development and introduction of vaccines to prevent diseases afflicting impoverished populations in the developing world.

The UM SOM is also home to the Institute of Human Virology (IHV) under the leadership of Robert C. Gallo, M.D.  The IHV is the first center in the U.S. to combine the disciplines of basic science, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders, most notably HIV.  Dr. Gallo, who is widely known for his pioneering research in the field of human retroviruses with his discoveries of, Il-2, HTLV-1 and HTLV-2, his co-discovery of HIV as the cause of AIDS, and his development of the HIV blood test, is The Homer & Martha Gudelsky Distinguished Professor of Medicine and Director of the Institute of Human Virology in the School of Medicine, and Co-Founder and Scientific Director of the Global Virus Network (GVN).

CONTACT: Christopher Hardwick[email protected]

SOURCE University of Maryland School of Medicine

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
The Internet of Things is in the early stages of mainstream deployment but it promises to unlock value and rapidly transform how organizations manage, operationalize, and monetize their assets. IoT is a complex structure of hardware, sensors, applications, analytics and devices that need to be able to communicate geographically and across all functions. Once the data is collected from numerous endpoints, the challenge then becomes converting it into actionable insight.
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
Consumer IoT applications provide data about the user that just doesn’t exist in traditional PC or mobile web applications. This rich data, or “context,” enables the highly personalized consumer experiences that characterize many consumer IoT apps. This same data is also providing brands with unprecedented insight into how their connected products are being used, while, at the same time, powering highly targeted engagement and marketing opportunities. In his session at @ThingsExpo, Nathan Trel...
Amazon and Google have built software-defined data centers (SDDCs) that deliver massively scalable services with great efficiency. Yet, building SDDCs has proven to be a near impossibility for ‘normal’ companies without hyper-scale resources. In his session at 17th Cloud Expo, David Cauthron, founder and chief executive officer of Nimboxx, will discuss the evolution of virtualization (hardware, application, memory, storage) and how commodity / open source hyper converged infrastructure (HCI) so...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
With the Apple Watch making its way onto wrists all over the world, it’s only a matter of time before it becomes a staple in the workplace. In fact, Forrester reported that 68 percent of technology and business decision-makers characterize wearables as a top priority for 2015. Recognizing their business value early on, FinancialForce.com was the first to bring ERP to wearables, helping streamline communication across front and back office functions. In his session at @ThingsExpo, Kevin Roberts...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...